Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Beta Bionics, Inc. Common Stock (BBNX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: BBNX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 31.38% | Avg. Invested days 16 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 945.12M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 8.89 - 24.50 | Updated Date 06/22/2025 |
52 Weeks Range 8.89 - 24.50 | Updated Date 06/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -104.64% | Operating Margin (TTM) -65.71% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 891525977 | Price to Sales(TTM) 17.82 |
Enterprise Value 891525977 | Price to Sales(TTM) 17.82 | ||
Enterprise Value to Revenue 16.81 | Enterprise Value to EBITDA - | Shares Outstanding 43334300 | Shares Floating 41336549 |
Shares Outstanding 43334300 | Shares Floating 41336549 | ||
Percent Insiders 6.74 | Percent Institutions 55.22 |
Upturn AI SWOT
Beta Bionics, Inc. Common Stock
Company Overview
History and Background
Beta Bionics, Inc. is a medical technology company focused on developing and commercializing innovative diabetes management solutions. Founded in 2015, it originated from research at Boston University. A significant milestone was the development and FDA clearance of the iLet Bionic Pancreas.
Core Business Areas
- Diabetes Management Systems: Development, manufacturing, and sales of automated insulin delivery (AID) systems, primarily the iLet Bionic Pancreas, designed to autonomously manage blood glucose levels in individuals with type 1 diabetes.
Leadership and Structure
Beta Bionics is led by a team of experienced executives and medical professionals. The organizational structure includes departments for research and development, clinical affairs, regulatory affairs, manufacturing, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- iLet Bionic Pancreas: An automated insulin delivery system that autonomously manages blood glucose levels in people with type 1 diabetes. It is designed to mimic a biological pancreas by automatically adjusting insulin dosing based on real-time glucose readings. Market share is growing, but specific data is limited due to the relatively recent launch. Competitors include Medtronic's MiniMed 780G, Tandem Diabetes Care's Control-IQ, and Insulet's Omnipod 5.
Market Dynamics
Industry Overview
The diabetes management market is experiencing significant growth, driven by the increasing prevalence of diabetes globally and technological advancements in insulin delivery systems and continuous glucose monitoring (CGM). The market is competitive, with established players and emerging companies vying for market share.
Positioning
Beta Bionics is positioned as an innovator in the AID market, particularly with its iLet Bionic Pancreas. Its competitive advantage lies in its fully automated system, designed to simplify diabetes management for users.
Total Addressable Market (TAM)
The global diabetes management market is estimated to be over $80 billion. Beta Bionics is positioned to capture a portion of this TAM with its innovative technology. The exact share depends on the ability to gain market share, expand into new geographic regions and successfuly adapt to changing regulatory landscapes.
Upturn SWOT Analysis
Strengths
- Innovative technology (iLet Bionic Pancreas)
- Strong clinical data supporting product efficacy
- Focus on automation and ease of use
- Dedicated management team
Weaknesses
- Limited market share compared to established players
- Reliance on a single key product
- Potential challenges in scaling production and distribution
- High R&D expenditure
Opportunities
- Expanding into new geographic markets
- Developing next-generation AID systems
- Partnering with healthcare providers and payers
- Integrating with other digital health platforms
Threats
- Competition from established players with greater resources
- Changing regulatory landscape for medical devices
- Pricing pressures and reimbursement challenges
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Tandem Diabetes Care (TNDM)
- Insulet (PODD)
Competitive Landscape
Beta Bionicsu2019s competitive advantage lies in its novel iLet product. However, it faces stiff competition from more established companies like Medtronic and Tandem, which have greater financial resources and established market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not publicly available, but growth is likely to occur in the near term as the company launches the iLet Bionic Pancreas.
Future Projections: Future growth projections are not available, but growth is expected to be strong in the short to medium term.
Recent Initiatives: Recent strategic initiatives include the FDA approval and launch of the iLet Bionic Pancreas and expanding its sales and marketing efforts to reach more patients.
Summary
Beta Bionics is an innovative company in the diabetes management space with a potentially game-changing product, the iLet Bionic Pancreas. While the company has a strong technological edge and positive clinical data, it is smaller and less established than its main competitors. Key factors to watch include the companyu2019s ability to scale production, expand its market reach, and manage competitive pressures in a rapidly evolving market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Analyst Reports
- FDA Documents
- Diabetes Industry News Sources
Disclaimers:
The information provided is based on available data and estimates and is subject to change. Market share data is approximate and may vary depending on the source. This analysis is for informational purposes only and should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Beta Bionics, Inc. Common Stock
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2025-01-30 | President, CEO & Director Mr. Sean T. Saint PE | ||
Sector Healthcare | Industry Medical Devices | Full time employees 352 | Website https://www.betabionics.com |
Full time employees 352 | Website https://www.betabionics.com | ||
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.